Sangamo Therapeutics Inc (SGMO) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Sangamo Therapeutics Inc (Sangamo), formerly Sangamo BioSciences Inc, is a clinical stage biotechnology company that focuses on the research, development and commercialization of engineered DNA-binding proteins (ZFPs) for gene regulation, cell therapy and therapeutic genome editing. Its product candidates targets the treatment of HIV/AIDS, hemophilia A and B, hurler syndrome (MPS I), fabry disease, Huntingtons disease and many others. Its ZFPs based products are used in various applications such as human therapeutics, research reagents, pharmaceutical protein production, plant agriculture, cell-line engineering and production of transgenic animals. The company has presence in the UK and the US. Sangamo is headquartered in Richmond, California, the US.

Sangamo Therapeutics Inc (SGMO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Kite Pharma to Enter into Licensing Agreement with Sangamo Therapeutics 11
Sangamo Therapeutics Enters into Licensing Agreement with Pfizer 13
Pfizer Enters into Licensing Agreement with Sangamo Therapeutics 14
Biogen Idec Enters into Licensing Agreement with Sangamo BioSciences for Hemoglobinopathies Therapeutics 15
Shire Amends Licensing Agreement with Sangamo BioSciences for ZFP Therapeutics 16
Sangamo BioSciences Enters into Licensing Agreement for mRNA Delivery Technology 18
Equity Offering 19
Sangamo Therapeutics Raises USD230 Million in Public Offering of Shares 19
Sangamo BioSciences Raises USD72.5 Million in Public Offering of Shares 21
Sangamo Therapeutics Raises USD83.4 Million in Public Offering of Shares 23
Sangamo BioSciences Completes Public Offering Of Shares For US$100 Million 25
Sangamo BioSciences Completes Public Offering Of Shares For US$74.2 Million 27
Asset Transactions 29
Bioverativ to Acquire Rights to Genome Editing Program from Sangamo BioSciences 29
Acquisition 30
Sangamo BioSciences Completes Acquisition Of Ceregene, Biotechnology Company 30
Sangamo Therapeutics Inc - Key Competitors 32
Sangamo Therapeutics Inc - Key Employees 33
Sangamo Therapeutics Inc - Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 35
Strategy And Business Planning 35
Nov 09, 2017: Sangamo Announces Plans For New Headquarters In Brisbane, California 35
Financial Announcements 36
May 08, 2018: Sangamo Therapeutics Reports First Quarter 2018 Financial Results 36
Feb 21, 2018: Sangamo Therapeutics Reports Fourth Quarter And Full Year 2017 Financial Results 38
Nov 09, 2017: Sangamo Therapeutics Reports Third Quarter 2017 Financial Results 39
Aug 09, 2017: Sangamo Therapeutics Reports Second Quarter 2017 Financial Results 41
May 10, 2017: Sangamo Therapeutics Reports First Quarter 2017 Financial Results 43
Feb 28, 2017: Sangamo Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results 44
Feb 27, 2017: Sangamo Therapeutics Announces Chief Financial Officer Succession 46
Corporate Communications 47
Jun 28, 2018: Sangamo Therapeutics Appoints Karen Smith to its Board of Directors 47
May 03, 2018: Sangamo Therapeutics Announces Senior Leadership Changes 48
Feb 12, 2018: Sangamo Therapeutics Appoints Heather D. Turner As Senior Vice President And General Counsel 49
Jun 29, 2017: Sangamo Therapeutics Appoints Roger Jeffs, Ph.D. and Joseph S. Zakrzewski to its Board of Directors 50
Apr 25, 2017: Sangamo Announces The Retirement Of Its Founder And Genome Editing Pioneer Edward Lanphier From The Board Of Directors 51
Government and Public Interest 52
Apr 27, 2018: Therapies Targeting Cancer, Deadly Immune Disorder and Life-Threatening Blood Condition Get Almost $32 Million Boost from Stem Cell Agency 52
Product News 54
11/01/2017: Bioverativ to Present New Data on ST-400 at ASH 2017 Annual Meeting 54
10/17/2017: Sangamo Therapeutics Announces Presentations At 2017 Annual Congress Of The European Society Of Gene And Cell Therapy 55
04/27/2018: Sangamo Announces $8 Million CIRM Grant For ST-400 -- A Gene-Edited Cell Therapy Candidate -- To Treat Transfusion-Dependent Beta-Thalassemia 56
Product Approvals 57
Oct 02, 2017: Sangamo And Bioverativ Announce FDA Acceptance of IND Application For ST-400 - A Gene-Edited Cell Therapy Candidate - to Treat Beta-Thalassemia 57
Jun 07, 2017: Sangamo Therapeutics And Pfizer Announce That SB-525 Investigational Hemophilia A Gene Therapy Receives Orphan Medicinal Product Designation From The European Medicines Agency 58
May 16, 2017: Sangamo Receives Fast Track Designation From The FDA For SB-525 Investigational Hemophilia A Gene Therapy 59
May 04, 2017: Sangamo Therapeutics Announces Orphan Drug Designation for SB-525 cDNA Gene Therapy for Hemophilia A 60
Feb 27, 2017: Sangamo Therapeutics Receives Rare Pediatric Disease Designation From FDA For SB-318 In Vivo Genome Editing Therapeutic For MPS I 61
Jan 11, 2017: Sangamo Therapeutics Receives Orphan Drug Designation from the FDA for SB-318 Genome Editing Treatment for MPS I 62
Jan 05, 2017: Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For SB-525 Gene Therapy Program For Hemophilia A 63
Clinical Trials 64
Feb 08, 2017: Sangamo Therapeutics Announces Data on SB-318 at The 13th Annual WORLDSymposium Meeting 64
Feb 08, 2017: Sangamo Therapeutics Announces Data on SB-913 at The 13th Annual WORLDSymposium Meeting 65
Other Significant Developments 66
Jan 06, 2017: Sangamo BioSciences Changes Name To Sangamo Therapeutics, Underscoring Focus On Clinical Development Of Genomic Therapies 66
Appendix 67
Methodology 67
About GlobalData 67
Contact Us 67
Disclaimer 67

List Of Tables

List of Tables
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sangamo Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Kite Pharma to Enter into Licensing Agreement with Sangamo Therapeutics 11
Sangamo Therapeutics Enters into Licensing Agreement with Pfizer 13
Pfizer Enters into Licensing Agreement with Sangamo Therapeutics 14
Biogen Idec Enters into Licensing Agreement with Sangamo BioSciences for Hemoglobinopathies Therapeutics 15
Shire Amends Licensing Agreement with Sangamo BioSciences for ZFP Therapeutics 16
Sangamo BioSciences Enters into Licensing Agreement for mRNA Delivery Technology 18
Sangamo Therapeutics Raises USD230 Million in Public Offering of Shares 19
Sangamo BioSciences Raises USD72.5 Million in Public Offering of Shares 21
Sangamo Therapeutics Raises USD83.4 Million in Public Offering of Shares 23
Sangamo BioSciences Completes Public Offering Of Shares For US$100 Million 25
Sangamo BioSciences Completes Public Offering Of Shares For US$74.2 Million 27
Bioverativ to Acquire Rights to Genome Editing Program from Sangamo BioSciences 29
Sangamo BioSciences Completes Acquisition Of Ceregene, Biotechnology Company 30
Sangamo Therapeutics Inc, Key Competitors 32
Sangamo Therapeutics Inc, Key Employees 33
Sangamo Therapeutics Inc, Subsidiaries 34

List Of Figures

List of Figures
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Sangamo Therapeutics Inc (SGMO) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Sangamo Therapeutics Inc (Sangamo), formerly Sangamo BioSciences Inc, is a clinical stage biotechnology company that focuses on the research, development and commercialization of engineered DNA-binding proteins (ZFPs) for gene regulation,

USD 250 View Report

Sangamo Therapeutics Inc (SGMO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Sangamo Therapeutics Inc (Sangamo), formerly Sangamo BioSciences Inc, is a clinical stage biotechnology company that focuses on the research, development and commercialization of engineered DNA-binding proteins (ZFPs) for gene regulation,

USD 250 View Report

BioClin Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

BioClin Therapeutics Inc (BioClin) is a clinical stage biotechnology company developing protein therapeutics for genetic disorders. Its lead product candidate B-701 is a human monoclonal antibody which targets the activity

USD 250 View Report

Torque Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Torque Therapeutics Inc (Torque) is an immuno-oncology company focused on developing first-in-class deep primed T Cell therapeutics to cure cancer. Its product pipeline includes Deep IL-15 used for for hematologic

USD 250 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available